Gapping up
In reaction to strong earnings/guidance: EJ +9.8%, TEDU +4.5%, AINV +2.1%, PWRD +2%, NPTN +1.1%.
M&A related: ARX +25.4% (to be acquired by Cobham plc for ~$1.46 bln; shareholders to receive $10.50 per share in cash), ARNA +4.6% (Hearing M&A speculation attributed to the move), AZN +2% (Retuers discusses comments from analysts that Pfizer (PFE) deal for AZN may not be dead yet).
Other news: OPHT +25.6% (co entered into ex-US licensing and commercialization agreement for Fovista with Novartis (NVS)), ONCY +11.1% (releases ASCO presentation, trial could pave the way for phase I/II trials and combination studies), NEWL +8.7% (cont strength), CLVS +7.5% (received breakthrough therapy designation for CO-1686 for the treatment of second-line EGFR mutant non-small cell lung cancer (NSCLC) in patients with the T790M Mutation), EW +2.9% (Edwards Lifesciences, Medtronic (MDT) agree to global transcatheter valve litigation settlement; all patent litigation between the companies to be dismissed; MDT will make a one-time payment to EW of $750 mln), NEON +2% (Director disclosed a 50K common stock purchase on May 19 at $3.77/share), PLUG+1.6% (cont volatility), CS +1.2% (confirmed a comprehensive and final settlement regarding all outstanding U.S. cross-border matters), MYGN +1.1% (Prolaris test predicts mortality risk in prostate cancer biopsy study), DATA +0.8% (positive comments on Mad Money).
Analyst comments: ACXM +3.8% (upgraded to Outperform from Market Perform at Wells Fargo), IRDM +2.5% (upgraded to Strong Buy from Outperform at Raymond James), CCL +2.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley), GLOP +1.6% (initiated with a Outperform at Clarkson Capital), ARUN +0.9% (initiated with a Outperform at Imperial Capital)
In reaction to strong earnings/guidance: EJ +9.8%, TEDU +4.5%, AINV +2.1%, PWRD +2%, NPTN +1.1%.
M&A related: ARX +25.4% (to be acquired by Cobham plc for ~$1.46 bln; shareholders to receive $10.50 per share in cash), ARNA +4.6% (Hearing M&A speculation attributed to the move), AZN +2% (Retuers discusses comments from analysts that Pfizer (PFE) deal for AZN may not be dead yet).
Other news: OPHT +25.6% (co entered into ex-US licensing and commercialization agreement for Fovista with Novartis (NVS)), ONCY +11.1% (releases ASCO presentation, trial could pave the way for phase I/II trials and combination studies), NEWL +8.7% (cont strength), CLVS +7.5% (received breakthrough therapy designation for CO-1686 for the treatment of second-line EGFR mutant non-small cell lung cancer (NSCLC) in patients with the T790M Mutation), EW +2.9% (Edwards Lifesciences, Medtronic (MDT) agree to global transcatheter valve litigation settlement; all patent litigation between the companies to be dismissed; MDT will make a one-time payment to EW of $750 mln), NEON +2% (Director disclosed a 50K common stock purchase on May 19 at $3.77/share), PLUG+1.6% (cont volatility), CS +1.2% (confirmed a comprehensive and final settlement regarding all outstanding U.S. cross-border matters), MYGN +1.1% (Prolaris test predicts mortality risk in prostate cancer biopsy study), DATA +0.8% (positive comments on Mad Money).
Analyst comments: ACXM +3.8% (upgraded to Outperform from Market Perform at Wells Fargo), IRDM +2.5% (upgraded to Strong Buy from Outperform at Raymond James), CCL +2.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley), GLOP +1.6% (initiated with a Outperform at Clarkson Capital), ARUN +0.9% (initiated with a Outperform at Imperial Capital)